Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC).

Tagrisso (osimertinib) - AstraZeneca

BBT-176 - Parataxis Korea

QLH11811 - Qilu Pharma

tigozertinib (BLU-945) - Sanofi

BPI-361175 - Betta Pharma

HS-10375 - Jiangsu Hansoh Pharma

silevertinib (BDTX-1535) - Black Diamond Therap

TQB3804 - Sino Biopharm

http://www.ncbi.nlm.nih.gov/pubmed/42603542

Harun M Patel; Vaibhav M Kadam

Aug 16, 2026